{
  "docId": "019de073-416f-70a9-9a67-b7603aefb8d6",
  "docSlug": "920131855bb64d70700de092a3a107b0",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 50 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 21,
  "pageCount": 50,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-416f-70a9-9a67-b7603aefb8d6/21",
  "deckHref": "/decks/019de073-416f-70a9-9a67-b7603aefb8d6",
  "deckJsonHref": "/decks/019de073-416f-70a9-9a67-b7603aefb8d6.json",
  "deckAnchorHref": "/decks/019de073-416f-70a9-9a67-b7603aefb8d6#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.48,
        "x": 0.48,
        "y": 0.16
      },
      "kind": "list",
      "text": "Accelerate growth engines of Salix and International\nStabilize key cash-generating businesses of Dermatology, Neurology and Generics\nRecovery of procedures in Asia Pacific, availability of inventory, and expansion will support Solta growth\nAchieve timelines and budgets for key R&D projects\nIncrease size, breadth, and depth of product pipeline through R&D and strategic BD investment\nEstablish a high performance, energized culture with a sense of urgency, ownership, and accountability\nBuild flattened and focused organization with new thinking and new capabilities with cost discipline focus\nUtilize cash generated from operations to improve leverage\nCommitted to evaluating the distribution of Bausch + Lomb as BHC works through patent litigation\nFlexibility to monetize an additional ~8.5% stake of Bausch + Lomb stake\nDrive towards target net leverage ratio ~6.5x-6.7x",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8b9c201-36d0-4330-8cdc-4a0c5f7eeea9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.42,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "list",
      "text": "1. Drive growth through operational excellence across the enterprise\n2. Intensify focus and operating rigor behind R&D and business development\n3. Cultivate a high-performance, results-oriented culture\n4. Progress strategic alternatives",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b727f39-4366-45cf-85a9-6d7aabc39bb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. See Slide 2 for further information on forward-looking statements.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f73bdc74-7a1c-4f1e-bcf3-0358da4881bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "2022 Bausch Pharma + Solta priorities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb0887fe-0eaf-4330-818e-d73494b9aa95",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "cef99330-754d-462e-82ad-0050dc7ab984",
      "evidence": "list/bullet: Accelerate growth engines of Salix and International",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 21,
      "beatId": "db104731-6671-4c31-8dc3-dd1d5ab9f3ab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Team",
      "beatSlug": "sequoia-pitch-team",
      "evidence": "The document highlights key priorities and takeaways",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "aabfe76f-ff26-4e88-b063-9aabd5afb9e9",
      "evidence": "The document emphasizes key actions underway and priorities for 2022",
      "position": 0,
      "objective": "Highlighting the importance of taking action",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}